Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 8;40(12):2990–3003. doi: 10.1161/ATVBAHA.120.315168

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors.

Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Kaplan-Meier plot for major adverse cardiac events (MACE) plus myocardial injury over 90 d. Kaplan-Meier curves show the cumulative incidence of 5P-MACE plus myocardial injury through 90 d of follow-up after treatment with study drug. The efficacy analysis was conducted in coronary artery disease (CAD) patients with high-risk features or acute coronary syndrome (ACS) who underwent cardiac catheterization ± percutaneous coronary intervention (PCI) and received the study drug as an adjunct to standard antiplatelet and anticoagulant therapies (n=85). The P value was calculated by the Gehan-Breslow-Wilcoxon test.